Role of Proton Pump Inhibitors in the Management of Peptic Ulcer
DOI:
https://doi.org/10.37285/ijpsn.2023.16.6.7Abstract
Proton pump inhibitors (PPIs) have been used to treat a variety of conditions affecting the upper gastrointestinal tract including gastroesophageal reflux disease (GERD), esophagitis, Zollinger-Ellison syndrome (ZES) and dyspepsia. PPIs are also useful in the treatment of Helicobacter pylori infection as well as the prevention of upper gastrointestinal tract ulcers and bleeding in patients who are taking non-steroidal anti-inflammatory drugs (NSAIDs). It is critical to get the best clinical response possible for people with an upper gastrointestinal peptic disorder. This is dependent on the PPI used. Although all members of this class suppress active parietal cell acid secretion in the same way, there are minor variations in pharmacokinetic characteristics, metabolism and FDA-approved therapeutic indications among PPIs. Regardless of this, each is successful in treating GERD and peptic ulcers. Despite their overall effectiveness, PPIs have certain drawbacks, including short plasma half-lives and the need for meal-associated dosing, which can cause breakthrough symptoms in some people, particularly at night. This article discusses the current indications for PPIs in the treatment of peptic ulcers, as well as their pharmacokinetics and pharmacodynamics.
Downloads
Metrics
Keywords:
Proton pump inhibitors, Helicobacter pylori, Gastroesophageal reflux disease, Zollinger Ellison syndrome, Prostaglandins, PharmacokineticsPublished
How to Cite
Issue
Section
References
Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. The Lancet. 2009 Oct 24;374(9699):1449-61.Abraham NS. Proton pump inhibitors: potential adverse effects. Current opinion in gastroenterology. 2012 Nov; 28 (6): 615-620.
Laucirica I, Iglesias PG, Calvet X. Peptic ulcer. Medicina Clínica (English Edition). 2023 Sep 11.
Ramakrishnan K, Salinas RC. Peptic ulcer disease. American family physician. 2007 Oct 1;76(7):1005-12.Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. The American journal of medicine. 2009 Oct; 122 (10): 896-903.
Khesbak AA. Study of Some Affecting Factors on the Infection with Peptic Ulcer. Ind. J. Pure App. Biosci. 2023;11(2):42-9.
Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017 Aug 5;390(10094):613-24.
Susser M. Causes of peptic ulcer: a selective epidemiologic review. Journal of Chronic Diseases. 1967 Jun 1;20(6):435-56.
Yeomans ND. The ulcer sleuths: The search for the cause of peptic ulcers. Journal of gastroentero-logy and hepatology. 2011 Jan; 26:35-41.
Chan FK, Leung WK. Peptic-ulcer disease. The Lancet. 2002 Sep 21;360(9337):933-41.Andersson T. Omeprazole drug interaction studies. Clinical pharmacokinetics.1991 Sep; 21 (3): 195- 212.
Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. The American journal of medicine. 2019 Apr 1;132(4):447-56.
Melcarne L, García-Iglesias P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Review of Gastroenterology & Hepatology. 2016 Jun 2;10(6):723-33.
Musumba C, Pritchard DM, Pirmohamed M. cellular and molecular mechanisms of NSAID‐induced peptic ulcers. Alimentary pharmacology & therapeutics. 2009 Sep;30(6): 517-31.
Dunlap JJ, Patterson S. Peptic ulcer disease. Gastroenterology Nursing. 2019 Sep 1;42(5):451-4.
Sharma S, Bhatia R, Vasudevan A. Abdominal pain and diarrhoea in peptic ulcer disease. Gastroenterology. 2021 Aug 1;161(2):e48-9.
Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Risk factors for the presence of symptoms in peptic ulcer disease. Clinical endoscopy. 2017 Nov 1;50(6):578-84.
Najm WI. Peptic ulcer disease. Primary Care: Clinics in Office Practice. 2011 Sep 1;38(3):383-94.
Tu TC, Lee CL, Wu CH, Chen TK, Chan CC, Huang SH, Lee SC. Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointestinal endoscopy. 1999 Mar 1;49(3): 302-6.
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori using invasive and noninvasive approaches. Journal of pathogens. 2018 May 22;2018.
Lin HJ. Role of proton pump inhibitors in the management of peptic ulcer bleeding. World journal of gastrointestinal pharmacology and therapeutics. 2010 Apr 4;1(2):51.
Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer. Alimentary pharmacology & therapeutics. 2001 Jul 9;15(7):917-26.
Clarrett DM, Hachem C. Gastroesophageal reflux disease (GERD). Missouri medicine. 2018 May;115(3):214.
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. Jama. 2020 Dec 22;324(24):2536-47.
Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology. 1973 Jul 1;65(1):140-65.
Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine. 2000 Nov 1;79(6):379-411.
Hung PD, Schubert ML, Mihas AA. Zollinger-Ellison syndrome. Current treatment options in gastroenterology. 2003 Apr;6:163-70.
Milosavljevic T, Kostić-Milosavljević M, Jovanović I, Krstić M. Complications of peptic ulcer disease. Digestive diseases. 2011 Nov 1;29(5):491-3.
Jones JI, Hawkey CJ. Physiology and organ-related pathology of the elderly: stomach ulcers. Best Practice & Research Clinical Gastroenterology. 2001 Dec 1;15(6):943-61.
Hunt RH, Camilleri M, Crowe SE, El-Omar EM, Fox JG, Kuipers EJ, Malfertheiner P, McColl KE, Pritchard DM, Rugge M, Sonnenberg A. The stomach in health and disease. Gut. 2015 Oct 1;64(10):1650-68.
Friendship RM. Gastric ulcers. Pig News and Information. 2003 Jul 9(2003):4-pp.
Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World Journal of Gastroenterology: WJG. 2014 May 5;20(18):5191.
Szabo S, Vattay P. Experimental gastric and duodenal ulcers: advances in Pathogenesis. Gastroenterology Clinics of North America. 1990 Mar 1;19(1):67-85.
Roberts‐Thomson IC. How did the ancient bacterium, Helicobacter pylori, cause an epidemic of chronic duodenal ulceration?. JGH Open. 2021 Jun;5(6):636-42.
Brooks FP. The pathophysiology of peptic ulcer disease. Digestive Diseases and Sciences. 1985 Nov;30:15S-29S.
Mertz HR, Walsh JH. Peptic ulcer pathophysiology. Medical Clinics of North America. 1991 Jul 1;75(4):799-814.
Silva MI, de Sousa FF. Gastric ulcer etiology. Peptic ulcer disease. 2011 Nov 4;1.
Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut. 1995 Nov;37(5):595.
Zhaxi Y, Meng X, Wang W, Wang L, He Z, Zhang X, Pu W. Duan-Nai-An, A Yeast probiotic, improves intestinal mucosa integrity and immune function in weaned piglets. Scientific reports. 2020 Mar 12;10(1):4556.
Hollander F. The two-component mucous barrier: its activity in protecting the gastroduodenal mucosa against peptic ulceration. AMA Archives of Internal Medicine. 1954 Jan 1;93(1):107-20.
Venables CW. Mucus, pepsin, and peptic ulcer. Gut. 1986 Mar;27(3):233.
Fornai M, Antonioli L, Rocchina C, Marco T, Blandizzi C. Pathophysiology of gastric ulcer development and healing: molecular mechanisms and novel therapeutic options. InPeptic ulcer disease 2011 (pp. 113-142). Jianyan Chai.
Bennett A, Fleshler B. Prostaglandins and the gastrointestinal tract. Gastroenterology. 1970 Nov 1;59(5):790-800.
Walt RP. Prostaglandins and peptic ulcer therapy. Scandinavian Journal of Gastroenterology. 1990 Jan 1;25(sup174):29-36.
Hawkey CJ, Walt RP. Prostaglandins for peptic ulcer: a promise unfulfilled. The Lancet. 1986 Nov 8;328(8515):1084-7.
Chu S, Schubert ML. Gastric secretion. Current Opinion in Gastroenterology. 2012 Nov 1;28(6):587-93.
Hersey SJ, Sachs G. Gastric acid secretion. Physiological reviews. 1995 Jan 1;75(1):155-89.
Aihara T, Nakamura E, Amagase K, Tomita K, Fujishita T, Furutani K, Okabe S. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacology & therapeutics. 2003 Apr 1;98(1):109-27.
Soll AH, Walsh JH. Regulation of gastric acid secretion. Annual Review of Physiology. 1979 Mar;41(1):35-53.
Komarov SA. Gastrin. Proceedings of the Society for Experimental Biology and Medicine. 1938 May;38(4):514-6.
Hurwitz A, Carter CA. The pharmacology of antiulcer drugs. DICP. 1989 Oct;23(10_suppl):S 10-6.
Ghara D, Mohapatra R, Mandal S, Purkait A, Ghosh P, Sethi B, Mazumder S, Saha A. Recent advances in formulation and development of proton pump inhibitors.
Shrikrushna JS, Sanjay RP, Avinash MS. Formulation and development of a capsule of moringa oleifera as anti-ulcer drug.
Sachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Alimentary pharmacology & therapeutics. 2006 Jun;23:2-8.
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Current gastroenterology reports. 2008 Dec;10(6):528-34.
Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacological Research. 2009 Mar 1;59(3):135-53.
Robinson M. The pharmacodynamics and pharmacokinetics of proton pump inhibitors–overview and clinical implications. Alimentary pharmacology & therapeutics. 2004 Nov;20:1-0.
Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002 Nov 20;66(2):67-78.
Dilger K, Zheng Z, Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. British journal of clinical pharmacology. 1999 Sep;48(3):438-44.
Sharma S, Pepin X, Burri H, Zheng L, Kuptsova‐Clarkson N, de Jong A, Yu T, MacArthur HL, Majewski M, Byrd JC, Furman RR. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors. Clinical Pharmacology in Drug Development. 2022 Nov;11(11):1294-307.
Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G, Mattellone A, Tolomelli A. Therapeutic peptides targeting PPI in clinical development: Overview, mechanism of action and perspectives. Frontiers in Molecular Biosciences. 2021 Jun 14;8:697586.
Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. European journal of drug metabolism and pharmacokinetics. 1998 Mar;23:19-26.
Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clinical pharmacokinetics. 1996 Jul;31:9-28.
Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2003 Oct;23(10P2):74S-80S.
Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clinical pharmacokinetics. 2005 May;44:441-66.
Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary pharmacology & therapeutics. 2000 Aug;14(8):963-78.
Andersson T. Omeprazole drug interaction studies. Clinical pharmacokinetics. 1991 Sep;21(3):195-212.
Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clinical pharmacokinetics. 2010 Aug;49:509-33.
Karaźniewicz-Łada M, Główka AK, Mikulska AA, Główka FK. Pharmacokinetic drug–drug interactions among antiepileptic drugs, including CBD, drugs used to treat COVID-19 and nutrients. International Journal of Molecular Sciences. 2021 Sep 3;22(17):9582.
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug safety. 2014 Apr;37(4):201-11.
Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane database of systematic reviews. 2006(1).
Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. European journal of internal medicine. 2017 Jan 1;37:19-24.
Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Diseases of the Esophagus. 2017 Sep;30(9):1.
Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro‐oesophageal reflux disease and peptic ulcer disease. Alimentary pharmacology & therapeutics. 2003 Sep;18(6):559-68.
Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World journal of gastroenterology: WJG. 2009 Feb 2;15(8):990.
Miwa H, Yamada T, Sato K, Ohta K, Ohkura R, Murai T, Nagahara A, Takei Y, Ogihara T, Sato N. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection. Digestive diseases and sciences. 2000 Jan;45:77-82.
Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. Journal of gastroenterology and hepatology. 2003 Dec;18(12):1392-8.
Horn J. The proton-pump inhibitors: similarities and differences. Clinical therapeutics. 2000 Mar 1;22(3):266-80.
Venkat PG, Longstreth GF. Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome. Official journal of the American College of Gastroenterology| ACG. 2022 Jun 1;117(6):1012-3.
Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger–Ellison syndrome. Expert opinion on pharmacotherapy. 2006 Feb 1;7(2):169-75.
Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection—comparison with omeprazole and lansoprazole. Alimentary Pharmacology & Therapeutics. 1999 Jun;13(6):741-6.
Mestrovic A, Perkovic N, Tonkic A, Sundov Z, Kumric M, Bozic J. Personalized Approach in Eradication of Helicobacter pylori Infection. Antibiotics. 2022 Dec 21;12(1):7.
Laucirica I, Iglesias PG, Calvet X. Peptic ulcer. Medicina Clínica (English Edition). 2023 Sep 11.
Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. American family physician. 2002 Jul 15;66(2):273-81.
Lodato F, Azzaroli F, Turco L, Mazzella N, Buonfiglioli F, Zoli M, Mazzella G. Adverse effects of proton pump inhibitors. Best practice & research Clinical gastroenterology. 2010 Apr 1;24(2):193-201.
Maideen NM. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Medical Journal. 2023 May;59(2):115.
McCarthy DM. Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship?. International journal of molecular sciences. 2020 Jan 19;21(2):662.
Waldum HL, Sørdal Ø, Fossmark R. Proton pump inhibitors (PPIs) may cause gastric cancer–clinical consequences. Scandinavian journal of gastroenterology. 2018 Jun 3;53(6):639-42.
Hagiwara T, Mukaisho KI, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011 May 1;60(5):624-30.
Boxer M. Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors. EJHaem. 2020 Nov;1(2):548-51.
DelSignore M, Jeong T, Denmark G, Feldman D, Shih A, Zukerberg L, Chung DC. Incidence and natural history of gastric high-grade dysplasia in patients with familial adenomatous polyposis syndrome. Gastrointestinal Endoscopy. 2023 Jan 1;97(1):25-34.
Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart, Lung and Circulation. 2018 Apr 1;27(4):443-50.
Abbasi S, Hosseinkhan N, Jandaghi NZ, Sadeghi K, Foroushani AR, Hassani SA, Yavarian J, Azad TM. Impact of human rhinoviruses on gene expression in pediatric patients with severe acute respiratory infection. Virus Research. 2021 Jul 15;300:198408.
Vastrad B, Vastrad C, Tengli A. Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods. 3 Biotech. 2020 Oct;10(10):422.
Zazzeron L, Alicandro G, Daccò V, Lanfranchi C, Bulfamante A, Sciarrabba CS, Corti F, Colombo C. Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study. Digestive and Liver Disease. 2023 Mar 1;55(3):360-5.
Fatima K, Almas T, Lakhani S, Jahangir A, Ahmed A, Siddiqui A, Rahim A, Qureshi SA, Arshad Z, Golani S, Musheer A. The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Tropical Medicine and Infectious Disease. 2022 Feb 28;7(3):37.
Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. Current treatment options in gastroenterology. 2014 Dec;12:414-23.
Zerr B, Vazquez A, Erstad BL. Infection risk and management strategies for patients with cirrhosis taking proton pump inhibitors. American Journal of Health-System Pharmacy. 2023 Apr 27:zxad089.
Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Archives of internal medicine. 2010 May 10;170(9):772-8.
Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor–associated hypomagnesemia: what do FDA data tell us?. Annals of Pharmacotherapy. 2013 Jun;47(6):773-80.
Peng CC, Tu YK, Lee GY, Chang RH, Huang Y, Bukhari K, Tsai YC, Fu Y, Huang HK, Munir KM. Effects of proton pump inhibitors on glycemic control and incident diabetes: a systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism. 2021 Nov 1;106(11):3354-66.
Mumtaz H, Ghafoor B, Saghir H, Tariq M, Dahar K, Ali SH, Waheed ST, Syed AA. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study. Annals of Medicine and Surgery. 2022 Oct 1;82:104762.
Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Therapeutic advances in drug safety. 2013 Jun;4(3):125-33.
